We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitrification Versus Slow Cooling of Human Cleavage Stage Embryos

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00886431
First Posted: April 23, 2009
Last Update Posted: December 2, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Vrije Universiteit Brussel
Information provided by (Responsible Party):
Bart CJM Fauser, UMC Utrecht
April 22, 2009
April 23, 2009
December 2, 2014
May 2009
May 2012   (Final data collection date for primary outcome measure)
The percent change of the ongoing pregnancy rate per patient/couple who use their thawed embryos (following a fesh embryo transfer which did not result in an ongoing pregnancy) from baseline (slow cooling) to end point (vitrification). [ Time Frame: ongoing pregnancy is established 10 weeks following the transfer of a frozen embryo ]
Same as current
Complete list of historical versions of study NCT00886431 on ClinicalTrials.gov Archive Site
  • post-thaw embryo survival rate [ Time Frame: 1 hour after thawing ]
  • ongoing pregnancy rate per patient using their thawed embryos (independent of whether they became pregnant following a fresh embryo transfer or not [ Time Frame: 10 weeks following transfer of frozen thawed embryo ]
  • implantation rate per thawed embryo [ Time Frame: 10 weeks after transfer of thawed embryo ]
  • implantation rate per transferred thawed embryo [ Time Frame: 10 weeks after transfer of thawed embryo ]
  • cumulative implantation rate per cryopreservation [ Time Frame: 10 weeks after thawed embryo transfer ]
  • ongoing pregnancy rate per frozen-thaw cycle [ Time Frame: 10 weeks following thawed embryo transfer ]
  • average number of frozen-thawed cycles per patient [ Time Frame: is variable ]
  • post thaw development (categorial) per thawed embryo [ Time Frame: 24 hours following thawing ]
  • average number of cryo-thaw cycles to ongoing pregnancy [ Time Frame: variable, up to 3 years ]
  • average number of thawed embryos to ongoing implantation [ Time Frame: variable, up to 3 years ]
  • Life birth rate [ Time Frame: 9 month after pregnancy test ]
  • post-thaw embryo survival rate [ Time Frame: 1 hour after thawing ]
  • ongoing pregnancy rate per patient using their thawed embryos (independent of whether they became pregnant following a fresh embryo transfer or not [ Time Frame: 10 weeks following transfer of frozen thawed embryo ]
  • implantation rate per thawed embryo [ Time Frame: 10 weeks after transfer of thawed embryo ]
  • implantation rate per transferred thawed embryo [ Time Frame: 10 weeks after transfer of thawed embryo ]
  • cumulative implantation rate per cryopreservation [ Time Frame: 10 weeks after thawed embryo transfer ]
  • ongoing pregnancy rate per frozen-thaw cycle [ Time Frame: 10 weeks following thawed embryo transfer ]
  • average number of frozen-thawed cycles per patient [ Time Frame: is variable ]
  • post thaw development (categorial) per thawed embryo [ Time Frame: 24 hours following thawing ]
  • average number of cryo-thaw cycles to ongoing pregnancy [ Time Frame: variable, up to 3 years ]
  • average number of thawed embryos to ongoing implantation [ Time Frame: variable, up to 3 years ]
Not Provided
Not Provided
 
Vitrification Versus Slow Cooling of Human Cleavage Stage Embryos
A Double Blinded, Randomised Controlled Trial Comparing the Effectiveness of Vitrification to Slow Cooling in Cryopreserving Human Preimplantation Embryos

Human embryos can be preserved for later transfers by freezing. Traditionally the slow cooling method has been used. About 70% of the embryos remain fully intact after thawing. However, the remaining 30% of the embryos become (partially) damaged, and this freezing damage reduces their chance to implant. Recently an ultra rapid freezing method, called vitrification has been developed. During vitrification no damaging ice crystals are formed and the embryo freezes in a glass like state.

It appears that the freezing damage is reduced when embryos are vitrified. Observational studies in humans indicate that embryos are successfully preserved by vitrification, as indicated by promising pregnancy rates following thawing. However, the effectiveness of vitrification in relation to slow cooling with respect to pregnancy rates has so far not been evaluated by a randomised, controlled trial. The aim of this study is to investigate whether vitrification significantly improves embryo survival and ongoing pregnancy rates when compared to embryos frozen by slow cooling.

time of allocation: following embryo selection

type of embryos: cleavage stage -, morula stage or early blastocyst stage embryo (day3 - day4 after oocyte collection)

cryoprotectants: sucrose, dimethylsulfoxide, ethyleneglycol

vitrification storage device: high security vitrification straws

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Infertility
Other: embryo vitrification
Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
Other Names:
  • vitrification
  • high security vitrification straws
  • Experimental: Vitrification
    The embryos of patients allocated to this arm will be cryopreserved by vitrification.
    Intervention: Other: embryo vitrification
  • No Intervention: Slow cooling
    The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
146
Not Provided
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • female patient age 35 years or less
  • embryos are obtained by in vitro fertilization (IVF) or intra cytoplasmatic spermatozoon injection (ICSI)
  • single embryo transfer
  • 1rst IVF/ICSI treatment with an embryo transfer
  • availability of cryopreservable embryos

Exclusion Criteria:

  • female patient age is 36 years or older
  • participants of oocyte donation program
  • participants of percutaneous spermatozoon aspiration (PESA) program
  • couples with a finite source of spermatozoa
  • absence of cryopreservable embryos
Sexes Eligible for Study: All
18 Years to 35 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium,   Netherlands
 
 
NCT00886431
Vitrification study
CCMO NL23499.000.08
METC 08/183
No
Not Provided
Not Provided
Bart CJM Fauser, UMC Utrecht
UMC Utrecht
Vrije Universiteit Brussel
Principal Investigator: Bart C Fauser, Prof.,MD,PhD UMC Utrecht
UMC Utrecht
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP